Evidence map›Paper›PMID 36238082›Full record

ArticleFrontiers in neuroscience2022

SARS-CoV-2, long COVID, prion disease and neurodegeneration.

Yuhai Zhao, Vivian R Jaber, Walter J Lukiw

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Insights into the Diagnosis, Treatment, and Management of Prion Diseases.CNS & neurological disorders drug targets · 2026
    Review
  2. Review
  3. 1-L Transcription in Prion Diseases.International journal of molecular sciences · 2024
    Article
  4. Mechanisms of long COVID: An updated review.Chinese medical journal pulmonary and critical care medicine · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuhai ZhaoDepartment of Cell Biology and Anatomy, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
Vivian R JaberLSU Neuroscience Center, LSU Health Sciences Center, New Orleans, LA, United States.
Walter J LukiwLSU Neuroscience Center, LSU Health Sciences Center, New Orleans, LA, United States.

Funding

microRNA (miRNA) signaling in Alzheimer's disease(AD)R01AG038834 · NIA · LSU HEALTH SCIENCES CENTER · PI BAZAN, NICOLAS G. · 2011 to 2020
$3.3M
Gene Expression in Alzheimer's DiseaseR01AG018031 · NIA · LSU HEALTH SCIENCES CENTER · PI LUKIW, WALTER J · 2001 to 2006
$1.4M
NIA NIH HHS R01 AG018031NIA NIH HHS R01 AG038834
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer's disease (AD)Creutzfeldt-Jacob disease (CJD)long COVID-19miRNA-146amiRNA-155prion disease (PrD)‘S1’ spike proteinSARS-CoV-2

Identifiers

PMID36238082
PMCPMC9551214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.